Investigational drug · Phase 2
HS235
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pulmonary Arterial Hypertension, Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "HS235"
First trial start
2026
Aug 19, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS235", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Arterial Hypertension
- Pulmonary Hypertension
- Heart Failure With Preserved Ejection Fraction
Approved drugs for the same conditions: High blood pressure (hypertension) · Heart failure · Pulmonary arterial hypertension · Cardiovascular and metabolic · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "HS235" as an intervention, largest first.
- HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection FractionPivotal-lookingRecruiting
35Pharma Inc., a GSK companyIndustry
NCT07123779 · 126 participants (planned) · Start Oct 21, 2026 · Primary completion Jan 2029
Drug: HS235 · For: Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction
Sites: Kansas City, Missouri; Greenville, South Carolina; Dallas, Texas
35Pharma Inc., a GSK companyIndustry
NCT07143448 · 90 participants (planned) · Start Aug 19, 2026 · Primary completion Mar 2028
Drug: HS235 · For: Pulmonary Arterial Hypertension
Sites: Tampa, Florida; Boston, Massachusetts; Providence, Rhode Island · 7 sites in all
35Pharma Inc., a GSK companyIndustry
NCT06714825 · 39 participants · Start Nov 28, 2024 · Primary completion Dec 2, 2025
Drug: HS235; Placebo · For: Overweight and Obesity
Sites: Québec, Canada
Newest research
PubMed records naming it or its code names, newest first.
- The regulatory effect of growth differentiation factor 11 on different cells.
Shao Y, Liu T, Wen X, et al. · Front Immunol 2023
- Expression of leukemia inhibitory factor and its receptors is increased during differentiation of human embryonic stem cells.
Aghajanova L, Skottman H, Strömberg AM, et al. · Fertil Steril 2006
- Comparative genomic hybridization and karyotyping of human embryonic stem cells reveals the occurrence of an isodicentric X chromosome after long-term cultivation.
Inzunza J, Sahlén S, Holmberg K, et al. · Mol Hum Reprod 2004
Also in development for Pulmonary Arterial Hypertension
- INS1009Treprostinil PalmitilPhase 37 trials
Insmed Incorporated · Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- IKT-001Phase 32 trials
Inhibikase Therapeutics · Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
- RalinepagAPD811Phase 32 trials
United Therapeutics · PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- SeralutinibPhase 32 trials
Gossamer Bio USA, Inc. · Pulmonary Arterial Hypertension
- NS-863Phase 22 trials
NS Pharma, Inc. · Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD), Pulmonary Arterial Hypertension
- APL-9796Phase 21 trial
Apollo Therapeutics Ltd · Pulmonary Arterial Hypertension
- DIAG723Phase 21 trial
Diagonal Therapeutics, Inc. · Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
- PF-07868489Phase 21 trial
Pfizer · Pulmonary Arterial Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.